HFpEF With Pulmonary Vascular Disease: A New Phenotype? HFpEF With Pulmonary Vascular Disease: A New Phenotype?
What do we know about the emerging clinical syndrome of pulmonary hypertension in HFpEF, and what do we still need to learn? This brief summarizes current knowledge of this newly recognized problem.European Heart Journal
Conclusion: These results suggest that CPS technology accurately quantifies heart and respiration rates and measure fluid change- in the lungs. Significance: The CPS has the potential to accurately monitor lung fluid status noninvasively and continuously in a clinical and outpatient setting. Early and efficient management of lung fluid status is key in managing chronic conditions such heart failure, pulmonary hypertension, and acute respiration distress syndrome.
(MedPage Today) -- PH is common in many rheumatologic conditions
CONCLUSION: Minimally invasive, isolated TV surgery as reoperation without caval occlusion and on the beating heart can be safe and may improve clinical outcome. PMID: 29672815 [PubMed - as supplied by publisher]
Conclusion Minimally invasive, isolated TV surgery as reoperation without caval occlusion and on the beating heart can be safe and may improve clinical outcome. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | Full text
This study aimed to analyze the clinical characteristics of LAM with elevated pulmonary artery pressure (PAP) and evaluate the potential efficacy of sirolimus. The study involved 50 LAM patients who underwent echocardiography. According to the tricuspid regurgitation velocity (TRV), these patients were divided into the TRV ≤ 2.8 m/s group and TRV> 2.8 m/s group. Both groups comprised 25 females with an average age of 38.6 8.1 and 41.5 8.9 years. In the TRV> 2.8 m/s group, the estimated systolic PAP (SPAP) was significantly elevated (52.08 12.45 mmHg vs. 30.24 5.25 mmHg,P
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and serious complication after pulmonary embolism (PE). Its incidence in the general population is around 3–30 cases per million. The incidence of CTEPH after acute PE ranges between 0.1 and 8.8% [1–5]. In a meta-analysis including 4047 PE patients, the incidence of CTEPH was 2.8% (95% CI 1.5–4.1) in "PE survivors" without major comorbidities . In studies not using objective diagnostic criteria to diagnose CTEPH, the pooled incidence was 6.3% (95% CI 4.1–8.4) .
American Journal of Roentgenology, Ahead of Print.
Conditions: Transient Tachypnea of the Newborn; PPHN Interventions: Other: modified Silverman scale; Diagnostic Test: echocardiography Sponsor: Princess Anna Mazowiecka Hospital, Warsaw, Poland Not yet recruiting
CONCLUSIONS: Multiple factors derived from dysfunctional ECs induced FoxM1 expression in SMCs and activated FoxM1-dependent SMC proliferation which contributes to pulmonary vascular remodeling and PH. Thus, targeting FoxM1 signaling represents a novel strategy for treatment of IPAH. PMID: 29664678 [PubMed - as supplied by publisher]
After the Dawn - Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2018 Apr 17;: Authors: Ogawa A, Matsubara H Abstract In the past 5 years, balloon pulmonary angioplasty (BPA) for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are deemed inoperable has undergone significant refinement. As a result, the procedure is now used worldwide and has become a promising therapeutic option for those patients. However, pulmonary endarterectomy remains the gold standard treatment for patients with CTEPH because the techniques and stra...